Top Page
Integrated Research Limited
(OTC:IRI)
Integrated Research Limited (IRI) vs. iShares MSCI Australia ETF (EWA)
Integrated Research Limited Business Overview & Revenue Model
Integrated Research Limited Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 68.26M | 68.26M | 83.29M | 69.83M | 62.87M | 78.49M |
| Gross Profit | 50.68M | 68.26M | 83.29M | 28.94M | 62.87M | 78.49M |
| EBITDA | 13.45M | 13.45M | 25.34M | -1.07M | 10.40M | 23.34M |
| Net Income | 13.36M | 13.36M | 27.13M | -29.23M | 1.54M | 7.93M |
Balance Sheet | ||||||
| Total Assets | 122.97M | 122.97M | 114.19M | 90.84M | 132.20M | 136.63M |
| Cash, Cash Equivalents and Short-Term Investments | 40.59M | 40.59M | 31.89M | 18.55M | 12.33M | 12.15M |
| Total Debt | 1.85M | 1.85M | 1.72M | 3.05M | 4.87M | 13.08M |
| Total Liabilities | 22.36M | 22.36M | 25.82M | 30.97M | 45.08M | 53.29M |
| Stockholders Equity | 100.62M | 100.62M | 88.36M | 59.87M | 87.11M | 83.34M |
Cash Flow | ||||||
| Free Cash Flow | 8.18M | 8.18M | 15.22M | 8.20M | 6.97M | 9.67M |
| Operating Cash Flow | 8.68M | 8.68M | 13.04M | 15.99M | 18.76M | 21.91M |
| Investing Cash Flow | 1.17M | 4.12M | 2.27M | -8.90M | -11.80M | -12.24M |
| Financing Cash Flow | -4.90M | -5.00M | -1.69M | -1.63M | -6.96M | -6.44M |
Integrated Research Limited Technical Analysis
Integrated Research Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | AU$59.60M | 4.37 | 13.76% | 6.06% | -18.05% | -51.45% | |
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
48 Neutral | AU$24.22M | -3.68 | -31.01% | ― | -3.43% | -40.65% | |
41 Neutral | AU$11.80M | -1.82 | -133.07% | ― | -4.90% | -52.78% | |
41 Neutral | AU$47.76M | -6.90 | ― | ― | 21.82% | 6.83% | |
35 Underperform | AU$85.35M | -15.26 | ― | ― | ― | ― |
Integrated Research Limited Corporate Events
Integrated Research Limited announced a change in the director’s interest, with Mr. Michael Hitz acquiring 150,500 ordinary shares through on-market trades. This acquisition reflects a significant personal investment by Mr. Hitz, potentially indicating confidence in the company’s future prospects and stability, which may positively influence stakeholder perceptions.
Integrated Research Limited has announced a change in the director’s interest, with Ms. Katherine Greenhill acquiring 90,000 ordinary shares through on-market trades. This acquisition, valued at $28,088.40, signifies a notable increase in Ms. Greenhill’s stake in the company, potentially impacting the company’s governance and shareholder dynamics.
At the 2025 Annual General Meeting of Integrated Research Limited, all resolutions were passed, including the remuneration report, the re-election of Mr. Michael Hitz, and the grant of performance rights to Mr. Ian Lowe. These outcomes reflect strong shareholder support and are likely to bolster the company’s governance and operational strategies, positively impacting its market position and stakeholder confidence.
Integrated Research Limited announced the CEO’s presentation at the 2025 Annual General Meeting, highlighting its strategic focus on enhancing user experience and performance management solutions. The presentation underscores the company’s commitment to leveraging its hybrid cloud platform and domain expertise to optimize operations and improve system visibility for major global organizations, positioning IR as a key player in the industry.
In its 2025 Annual General Meeting, Integrated Research Limited reported a solid profit performance despite challenges in customer renewals, supported by strong customer demand and cost management. The company maintains a robust balance sheet with no debt, allowing for strategic investments in innovation aimed at sustainable shareholder returns. The operating environment has shifted, with Microsoft dominating the small to mid-tier market in the Collaborate segment, prompting IR to focus on large enterprises with complex multi-vendor environments. Despite facing customer churn and market saturation in its legacy products, IR is committed to its product-led growth strategy to unlock new revenue streams and secure long-term growth.
Integrated Research Limited has announced a trading update for the half-year ending December 2025, highlighting the momentum of its product-led growth strategy with increased investments and new product launches. Despite these efforts, the company anticipates softer revenue compared to the previous year due to weaker renewals and increased allowances for expected credit losses, leading to an expected EBITDA loss ranging from $3 million to $8 million.
Integrated Research Limited has released its 2025 Annual Report, highlighting its continued focus on optimizing operations of mission-critical systems and enhancing user experience. The report underscores the company’s strategic positioning in the global market for performance management solutions, emphasizing its role in enabling seamless transactions and collaborations for major organizations worldwide.
Integrated Research Limited has announced that its 2025 Annual General Meeting will be held on November 24, 2025. The company also stated that nominations for director positions must be submitted by September 26, 2025. This meeting is significant for stakeholders as it provides an opportunity to influence the company’s governance and strategic direction.
Integrated Research Limited has announced the quotation of 3,239,095 fully paid ordinary securities on the Australian Securities Exchange (ASX) as of September 15, 2025. This move is part of the company’s strategy to enhance its market presence and provide liquidity to its stakeholders, potentially impacting its operational capabilities and industry positioning positively.